Hypha Discovery is a UK-based biotechnology company that supports pharmaceutical and agrochemical companies by producing metabolites and new derivatives of drugs and pesticides in discovery and development. Hypha is an expert in the scalable synthesis of drug metabolites and oxidised derivatives of lead compounds, and possess a wealth of experience in the production, purification and structure elucidation of natural products.
NEW PolyCYPs® biocatalysis kits
Hypha’s PolyCYPs® kits provide a fast and scalable way to access CYP-derived drug metabolites and derivatives formed by oxidation at aliphatic or aromatic moieties. Download a pdf of the PolyCYPs brochure.
NEWS & EVENTS
Come and meet us at the following events
Interfacing Chemical Biology and Drug Discovery
55th International Conference on Medicinal Chemistry
3rd-5th July 2019, Nantes, France
Come and see us at Booth 34
We are also presenting a poster (PO95) on “Late Stage Functionalisation of Drug Candidates using PolyCYPs Enzymes.”
12th International Meeting
28th-31st July 2019, Portland, Oregon, USA
Visit us at Booth 100
We are looking forward to presenting two posters at ISSX this year.
One is a joint poster with Cyclerion Therapeutics on “Use of Microbial Biotransformation to Produce Scalable Quantities of a Glucuronidated Metabolite of the Clinical Stage Soluble Guanylate Cyclase Stimulator Praliciguat” (P10).
Our other poster is on “Accessing Mammalian Drug Metabolites using PolyCYPs Enzymes” (P25)
8th – 11th September 2019, Cambridge UK
Come and see us at Stand X
Download a copy of our brochure on drug metabolites and C-H activated derivatives
Our brochure on drug metabolites and C-H activated derivatives is now available. Inside we feature interesting case studies and client projects, including the following topics:
- Phase l CYP and non-CYP metabolites
- Phase ll conjugated metabolites such as glucuronides and sulfates
- Isotopically labelled metabolites
- Lead diversification / late stage functionalization
- Production of polar derivatives of drug lead compounds
Let us know if you would like a copy of a new paper published in Xenobiotica entitled Microbial Biotransformation – An Important Tool for the Study of Drug Metabolism, which describes some interesting projects Hypha have undertaken for Merck and Janssen with several difficult-to-synthesise hydroxylated and glucuronidated metabolites. Read the abstract at http://bit.ly/2xb6H9d
In a recent newsletter we look at the use of microbial biotransformation to produce scalable quantities of glucuronides, focussing on the synthesis of acyl glucuronides of carboxylic acid-containing drugs.